Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism

Circulation. 2012 Jan 3;125(1):159-64; discussion 164. doi: 10.1161/CIRCULATIONAHA.111.031146.

Authors

Christopher B Granger¹, Luciana V Armaganijan

Affiliation

¹ Duke Clinical Research Institute, 2400 Pratt St, Room 0311, Terrace Level, Durham, NC 27705, USA. grang001@mc.duke.edu

PMID: 22215890
DOI: 10.1161/CIRCULATIONAHA.111.031146

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Administration, Oral
Anticoagulants / administration & dosage*
Atrial Fibrillation / drug therapy*
Atrial Fibrillation / epidemiology
Cardiotonic Agents / administration & dosage*
Humans
Randomized Controlled Trials as Topic
Risk Factors
Stroke / drug therapy*
Stroke / epidemiology
Thromboembolism / epidemiology
Thromboembolism / prevention & control*

Substances

Anticoagulants
Cardiotonic Agents